M. Scott Harris, M.D., is a distinguished physician and biopharmaceutical executive with over two decades of experience in clinical development, regulatory affairs, and medical leadership. He earned his medical degree from the Johns Hopkins University School of Medicine and completed his residency in internal medicine at the University of Pennsylvania, followed by a fellowship in gastroenterology at the University of California, San Francisco. Dr. Harris has held prominent positions at several innovative biotech firms, including serving as Chief Medical Officer at Avaxia Biologics and Ocera Therapeutics, where he spearheaded the development of novel therapies for gastrointestinal and liver diseases. His expertise in designing and executing clinical trials has been instrumental in advancing treatments from early-stage research to regulatory approval, earning him recognition as a thought leader in hepatology and immunology. Throughout his career, Dr. Harris has achieved notable milestones, such as leading the successful Phase 3 trials for therapies targeting non-alcoholic steatohepatitis (NASH) and hepatic encephalopathy, which resulted in key FDA approvals and partnerships with major pharmaceutical companies. He has authored numerous peer-reviewed publications in prestigious journals like The New England Journal of Medicine and Gastroenterology, and he frequently presents at international conferences on topics related to liver disease and immunotherapy. His strategic insights have also guided multiple companies through mergers and acquisitions, enhancing their pipelines and investor value. As Chief Medical Officer at Altimmune Inc., Dr. Harris oversees the clinical development of the company's innovative immunotherapeutic pipeline, focusing on obesity, liver diseases, and infectious diseases. He plays a pivotal role in advancing Altimmune's lead candidates, such as pemvidutide for obesity and non-alcoholic fatty liver disease, by directing global clinical trials, ensuring regulatory compliance, and collaborating with cross-functional teams to bring cutting-edge treatments to patients. Under his leadership, Altimmune has made significant progress in its Phase 2 and Phase 3 programs, positioning the company as a key player in the biopharmaceutical landscape.